NOVAVAX INC

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

NVAX$10.20-6.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Consolidated Financial Statements

Item 1. Financial Statements

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share information)

	For the Three Months EndedMarch 31,
	2025	2024
Revenue:
Product sales	$621,678	$89,836
Licensing, royalties, and other	44,977	4,019
Total revenue	666,655	93,855
Expenses:
Cost of sales	14,115	59,209
Research and development	88,937	92,679
Selling, general, and administrative	48,090	86,798
Total expenses	151,142	238,686
Income (loss) from operations	515,513	(144,831)
Other income (expense):
Interest expense	(5,723)	(4,111)
Other income, net	10,056	3,654
Income (loss) before income tax expense	519,846	(145,288)
Income tax expense	1,200	2,262
Net income (loss)	$518,646	$(147,550)
Net income (loss) per share:
Basic	$3.22	$(1.05)
Diluted	$2.93	$(1.05)
Weighted average number of common shares outstanding:
Basic	161,049	139,916
Diluted	177,625	139,916

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

	For the Three Months EndedMarch 31,
	2025	2024
Net income (loss)	$518,646	$(147,550)
Other comprehensive income (loss):
Net unrealized gain on available-for-sale marketable securities	589	—
Foreign currency translation adjustment	23,578	(13,547)
Other comprehensive income (loss)	24,167	(13,547)
Comprehensive income (loss)	$542,813	$(161,097)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.